Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Paeds Vivasnephrology-urology-fluids-and-electrolytes

Paeds Vivas · nephrology-urology-fluids-and-electrolytes

Polycystic kidney disease and inherited nephropathies: Viva

Branching structured oral on paediatric polycystic kidney disease and inherited nephropathies: the gene-based classification of ARPKD, ADPKD, Alport syndrome and nephronophthisis, the ciliary and basement membrane mechanisms, the disease-specific therapies of tolvaptan and early ACE inhibition, and the multidisciplinary management of hepatic fibrosis and renal replacement.

branching clinical structured oral4 min readVerification in progress

Target exams

RACP DWERACP DCEMRCPCH Clinical
On this page
Study tools

Target exams

RACP DWERACP DCEMRCPCH Clinical
Prompt
A 6-year-old boy presents with persistent microscopic haematuria found on a school health check. His mother has a history of microscopic haematuria, and his maternal uncle developed kidney failure in his twenties and wears hearing aids. The examiner asks how you would investigate and manage this child.

Branch 1: The diagnosis and its genetic basis

The candidate should recognise this as probable X-linked Alport syndrome. The combination of persistent microscopic haematuria in a boy, a mother with haematuria suggesting she is a carrier, and a maternal uncle with kidney failure and hearing loss, points to a COL4A5 mutation on the X chromosome. The candidate should state that Alport syndrome results from mutations in the type IV collagen genes, with COL4A5 causing the X-linked form that accounts for about 85 percent of cases, and COL4A3 or COL4A4 causing autosomal recessive or dominant forms. The type IV collagen alpha-3, alpha-4 and alpha-5 chains form a specialised network in the glomerular basement membrane, lens capsule and cochlea, and their absence causes progressive basement membrane thinning, splitting and thickening, producing the haematuria, the eventual hearing loss and the ocular features. [1]

If the examiner asks what investigations would confirm the diagnosis, the candidate should propose genetic testing as the primary approach. A next-generation sequencing panel covering COL4A3, COL4A4 and COL4A5 would identify the pathogenic variant, confirm the inheritance pattern, and enable cascade testing of at-risk relatives. The candidate should mention that the 2024 ERKNet guideline recommends genetic testing for all suspected cases of Alport syndrome. If genetic testing is inconclusive, a renal biopsy with electron microscopy showing the lamellated, thickened glomerular basement membrane is definitive. Pure-tone audiometry should be performed from about age five and repeated annually, and ophthalmology review should look for anterior lenticonus and macular flecks. [3]

If pressed on the differential diagnosis, the candidate should distinguish Alport syndrome from benign familial haematuria from heterozygous COL4A3 or COL4A4 (thin basement membrane nephropathy), which carries a much milder course though it can progress in some families, and from IgA nephropathy, which presents with episodic gross haematuria following infection rather than persistent microscopic haematuria. The family history of hearing loss and kidney failure in an X-linked pattern is the key discriminator for Alport syndrome. [1]

Paediatrics Fellowship Pro

Continue reading

You have read the opening of this viva. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship library.

Sign in to continueSee pricing
References4ShowHide
  1. [1]Kashtan CE, Gross O Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020. Pediatr Nephrol, 2021.PMID 33159213
  2. [2]Bergmann C, Guay-Woodford LM, Harris PC, Horie S, et al Polycystic kidney disease. Nat Rev Dis Primers, 2018.PMID 30523303
  3. [3]Torra R, Lipska-Zietkiewicz B, Acke F, et al Diagnosis, management and treatment of the Alport syndrome - 2024 guideline on behalf of ERKNet, ERA and ESPN. Nephrol Dial Transplant, 2025.PMID 39673454
  4. [4]Wolf MTF, Bonsib SM, Larsen CP, Hildebrandt F Nephronophthisis: a pathological and genetic perspective. Pediatr Nephrol, 2024.PMID 37930417
Paediatrics Fellowship Pro

$29/ monthor $279 / year

The complete Paediatrics Fellowship library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousOliguria, anuria and urinary obstruction: Vivanephrology-urology-fluids-and-electrolytesNextPolyuria and polydipsia — vivanephrology-urology-fluids-and-electrolytes